Bill in Maryland Amended to Exempt Pharma MR Incentives for Doctors - H.B. 818 - Articles

Articles

Stay at the forefront of the consumer insights and analytics industry with our Thought Leadership content. Here you’ll find timely updates on the Insights Association’s advocacy efforts, including the latest legislative and regulatory developments that impact how we work. In addition, this section offers expert perspectives on innovative research techniques and methodologies, as well as valuable analysis of evolving consumer trends. Together, these insights provide a trusted resource for professionals looking to navigate change, elevate their practice, and shape the future of our industry.

Bill in Maryland Amended to Exempt Pharma MR Incentives for Doctors - H.B. 818

Maryland Delegate Nic Kipke (R-31) withdrew H.B. 818, which would have banned most payments from pharmaceutical and medical device manufacturers to health care professionals, likely including incentives for participation in marketing research.

MRA Action

MRA testified on this bill on March 3 at a hearing of the House Healthcare and Government Operations Committee in Annapolis.

After extensive discussions with MRA, Delegate Kipke had agreed to amend H.B. 818 to exclude, “Payments to health care professionals for participation in bona fide marketing research conducted by a third party, where such payments are made by that third party and the sponsoring manufacturer is unaware of the identify of the participating health care professionals.”

The amendment would have defined “bona fide marketing research” to mean “the collection and analysis of data regarding opinions, needs, awareness, knowledge, views and behaviors of a population, through the administration of surveys, interviews, focus groups, polls, observation, or other research methodologies, in which no sales, promotional or marketing efforts are involved and through which there is no attempt to influence a participant’s attitudes or behavior.”

Conclusion

Since this amendment would have protected incentives for research with health care professionals, MRA supported H.B. 818 as amended. We will continue to work with Delegate Kipke should he return to working on this sort of legislation in the future.

Attachments

  1. kipke_pharma_mr_amendment_2011.pdf 6/28/2022 9:25:53 PM

Related

Share

Login

Members only Article - Please login to view
  • Back to top